Induced pluripotent stem cell-derived cardiomyocytes provide a platform for studying the pathophysiology of arrhythmogenic heart diseases and hold potential for personalized medicine and drug safety testing.
Supports iPSC-CM arrhythmia modeling; leaves open clinical translation to personalized medicine or drug testing.
Induced pluripotent stem cells offer the possibility to generate patient-specific stem cell lines from individuals affected by inherited disorders. Cardiomyocytes differentiated from such patient-specific induced pluripotent stem cells lines have been used to study the pathophysiology of arrhythmogenic heart diseases, such as the long-QT syndrome or catecholaminergic polymorphic ventricular tachycardia. Testing for unwanted drug side effects or tailoring medical treatment to the specific needs of individual patients with arrhythmogenic disorders may become future applications of this emerging technology.
No takes yet. Share an insight, caveat, or question.
Sinnecker et al. (2013) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: